ACT Brief: Lilly Seeks FDA Priority Review for Oral GLP-1 as Bispecific Antibody Trials Redefine Ethical Standards | Applied Clinical Trials Online
ACT Brief: Lilly Seeks FDA Priority Review Eli Lilly's orforglipron may become the first oral GLP-1 therapy reviewed under FDA's new national priority program. Bispecific antibody r…